Two venture capitalists dissect why biotech burns billions while China runs trials in weeks—and why the next Genentech won’t look anything like the last one. Elliot Hershberg reveals the “three horsemen” strangling drug development as costs explode to $2.5 billion per approval, while Lada Nuzhna exp
Can America Win The AI Biotech Race Against China? | Lada Nuzhna & Elliot Hershberg

Can America Win The AI Biotech Race Against China? | Lada …
a16z Podcast
0:00
--:--